{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:35Z","timestamp":1765382435889,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science, Technology & Innovation Funding Authority"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with severe uncontrolled asthma still experience acute asthma symptoms and exacerbations, particularly those with non-eosinophilic inflammation who take the maximum amount of standard drug therapy. Tezepelumab, a human monoclonal antibody, can improve lung function and enhance control of asthma symptoms in those patients, regardless of the disease\u2019s baseline characteristics. This study aims to investigate the safety and efficacy of using tezepelumab in controlling severe symptoms of uncontrolled asthma. We performed a comprehensive literature search in several databases, including PubMed, Scopus, Web of Science, Cochrane Library, and clinicaltrial.gov, using a well-established search strategy to include all relevant publications. According to our inclusion criteria, we searched for randomized controlled trials comparing tezepelumab versus placebo in patients with severe, uncontrolled asthma. We analyzed the data using The Revman 5.4 program software. The search identified 589 potential articles. After excluding studies inconsistent with selection criteria, four studies were included and analyzed qualitatively and quantitatively. The pooled effect demonstrated the better performance of tezepelumab over the placebo regarding the decrease in annualized asthma exacerbation rate (MD\u2009=\u2009\u2212\u00a00.74, (95% CI [\u2212\u00a01.04, \u2212\u00a00.44], p\u2009&lt;\u20090.00001)), asthma control questionnaire-6 (ACQ-6) Score MD\u2009=\u2009\u2212\u00a00.32, (95% CI [\u2212\u00a00.43, \u2212\u00a00.21], p\u2009&lt;\u20090.00001)), blood eosinophil count (MD\u2009=\u2009\u2212\u00a0139.38 cells\/mcL, (95% CI [\u2212\u00a0150.37, \u2212\u00a0128.39], p\u2009&lt;\u20090.00001)), feNO (MD\u2009=\u2009\u2212\u00a010\u00a0ppb, (95% CI [\u2212\u00a015.81, \u2212\u00a04.18], p\u2009=\u20090.0008)) and serum total IgE (MD\u2009=\u2009\u2212\u00a0123.51 UI\/ml, (95% CI [\u2212\u00a0206.52, \u2212\u00a040.50], p\u2009=\u20090.004)). All tezepelumab groups had higher pre-bronchodilator forced expiratory volume in 1\u00a0s than the placebo group (MD\u2009=\u20090.16, (95% CI [0.10, 0.21], p\u2009&lt;\u20090.00001)). Higher efficacy and safety profile was detected for tezepelumab to control the exacerbations of severe uncontrolled adult asthmatics.\n<\/jats:p>","DOI":"10.1038\/s41598-022-24763-9","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:03:29Z","timestamp":1670069009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Mahmoud","family":"Shaban Abdelgalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa","family":"Ahmed Elrashedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed K.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Reda Gad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramadan","family":"Abdelmoez Farahat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassant","family":"Hassan Shawki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-9161","authenticated-orcid":false,"given":"Mohamed","family":"Abd-ElGawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"24763_CR1","volume-title":"Pocket Guide for Asthma Management and Prevention: (For Adults and Children Older than 5 Years)","author":"Global Initiative for A","year":"2018","unstructured":"Global Initiative for A. Pocket Guide for Asthma Management and Prevention: (For Adults and Children Older than 5 Years) (Global Initiative for Asthma, 2018)."},{"key":"24763_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-12-204","volume":"12","author":"T To","year":"2012","unstructured":"To, T. et al. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health 12, 1\u20138 (2012).","journal-title":"BMC Public Health"},{"key":"24763_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy, J. V. Type 2 inflammation in asthma\u2014Present in most, absent in many. Nat. Rev. Immunol. 15, 57\u201365 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"24763_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1365-2222.2011.03917.x","volume":"42","author":"CE Brightling","year":"2012","unstructured":"Brightling, C. E., Gupta, S., Gonem, S. & Siddiqui, S. Lung damage and airway remodelling in severe asthma. Clin. Exp. Allergy 42, 638\u2013649 (2012).","journal-title":"Clin. Exp. Allergy"},{"key":"24763_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fmed.2020.00191","volume":"7","author":"KP Hough","year":"2020","unstructured":"Hough, K. P. et al. Airway remodeling in asthma. Front. Med. 7, 191 (2020).","journal-title":"Front. Med."},{"key":"24763_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1164\/ajrccm\/145.3.669","volume":"145","author":"AF Walls","year":"1992","unstructured":"Walls, A. F., Roche, W. R., Howarth, P. H. & Holgate, S. T. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma1-3. Am. Rev. Respir. Dis. 145, 669\u2013714 (1992).","journal-title":"Am. Rev. Respir. Dis."},{"key":"24763_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse, W. W. et al. BORA study investigators long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir. Med. 7, 46\u201359 (2019).","journal-title":"Lancet Respir. Med."},{"key":"24763_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","volume":"35","author":"WW Busse","year":"2018","unstructured":"Busse, W. W. et al. Quest LA. Phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma. Adv. Ther. 35, 737\u201348 (2018).","journal-title":"Adv. Ther."},{"key":"24763_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003559.pub4","author":"R Normansell","year":"2014","unstructured":"Normansell, R., Walker, S., Milan, S. J., Walters, E. H. & Nair, P. Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD003559.pub4 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"24763_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","volume":"197","author":"TF Carr","year":"2018","unstructured":"Carr, T. F., Zeki, A. A. & Kraft, M. Eosinophilic and noneosinophilic asthma. Am. J. Respir. Crit. Care Med. 197, 22\u201337 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"24763_CR11","doi-asserted-by":"publisher","first-page":"2000528","DOI":"10.1183\/13993003.00528-2020","volume":"57","author":"TSC Hinks","year":"2021","unstructured":"Hinks, T. S. C., Levine, S. J. & Brusselle, G. G. Treatment options in type-2 low asthma. Eur. Respir. J. 57, 2000528 (2021).","journal-title":"Eur. Respir. J."},{"key":"24763_CR12","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s41590-019-0524-9","volume":"20","author":"J Corren","year":"2019","unstructured":"Corren, J. & Ziegler, S. F. TSLP: From allergy to cancer. Nat. Immunol. 20, 1603\u20131609 (2019).","journal-title":"Nat. Immunol."},{"key":"24763_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau, G. M., Sehmi, R., Ambrose, C. S. & Griffiths, J. M. Thymic stromal lymphopoietin: Its role and potential as a therapeutic target in asthma. Expert Opin. Ther. Targets 24, 777\u2013792 (2020).","journal-title":"Expert Opin. Ther. Targets"},{"key":"24763_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cbf.2926","volume":"31","author":"J Wu","year":"2013","unstructured":"Wu, J. et al. Thymic stromal lymphopoietin promotes asthmatic airway remodelling in human lung fibroblast cells through STAT3 signalling pathway. Cell Biochem. Funct. 31, 496\u2013503 (2013).","journal-title":"Cell Biochem. Funct."},{"key":"24763_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren, J. et al. Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 377, 936\u2013946 (2017).","journal-title":"N. Engl. J. Med."},{"key":"24763_CR16","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","volume":"370","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau, G. M. et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 370, 2102\u20132110 (2014).","journal-title":"N. Engl. J. Med."},{"key":"24763_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst. Rev. 10, 1\u201311 (2021).","journal-title":"Syst. Rev."},{"key":"24763_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2008","unstructured":"Higgins, J. P. T., Green, S. & Cochrane, C. Cochrane Handbook for Systematic Reviews of Interventions (Wiley-Blackwell, 2008)."},{"key":"24763_CR19","unstructured":"Global strategy for asthma management and prevention updated. http:\/\/ginasthma.org. Accessed 21 May 2022. (2012)."},{"key":"24763_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"key":"24763_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins, J. P. T. Measuring inconsistency in meta-analyses. BMJ 327, 557\u2013560 (2003).","journal-title":"BMJ"},{"key":"24763_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997).","journal-title":"BMJ"},{"key":"24763_CR23","doi-asserted-by":"publisher","first-page":"A2677","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A2677","volume-title":"B21. Severe Asthma: Clinical and Mechanistic Studies","author":"TH Pham","year":"2019","unstructured":"Pham, T. H., Ren, P., Parnes, J. R. & Griffiths, J. M. Tezepelumab reduces multiple key inflammatory biomarkers in patients with severe, uncontrolled asthma in the phase 2b PATHWAY study. In B21. Severe Asthma: Clinical and Mechanistic Studies (eds Pham, T. H. et al.) A2677 (American Thoracic Society, 2019)."},{"key":"24763_CR24","volume-title":"Immunobiology: The Immune System in Health and Disease","author":"CA Janeway Jr","year":"2001","unstructured":"Janeway, C. A. Jr., Travers, P., Walport, M. & Shlomchik, M. J. The production of IgE. In Immunobiology: The Immune System in Health and Disease 5th edn (eds Janeway, C. A., Jr. et al.) (Garland Science, 2001).","edition":"5"},{"key":"24763_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jaci.2009.01.059","volume":"123","author":"Z Allakhverdi","year":"2009","unstructured":"Allakhverdi, Z., Comeau, M. R., Jessup, H. K. & Delespesse, G. Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. J. Allergy Clin. Immunol. 123, 958\u2013960 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"24763_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","volume":"39","author":"J Tanaka","year":"2009","unstructured":"Tanaka, J. et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin. Exp. Allergy 39, 89\u2013100 (2009).","journal-title":"Clin. Exp. Allergy"},{"key":"24763_CR27","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/biomedicines9091281","volume":"9","author":"L Calzetta","year":"2021","unstructured":"Calzetta, L. et al. The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: A systematic review. Biomedicines 9, 1281 (2021).","journal-title":"Biomedicines"},{"key":"24763_CR28","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow, A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med. 384, 1800\u20131809 (2021).","journal-title":"N. Engl. J. Med."},{"key":"24763_CR29","first-page":"4334","volume":"9","author":"J Corren","year":"2021","unstructured":"Corren, J. et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J. Allergy Clin. Immunol. 9, 4334\u201342 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"24763_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.anai.2020.10.008","volume":"126","author":"J Corren","year":"2021","unstructured":"Corren, J. et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann. Allergy Asthma Immunol. 126, 187\u2013193 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"24763_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro, M. et al. Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study. Lancet Respir. Med. 2, 879\u2013890 (2014).","journal-title":"Lancet Respir. Med."},{"key":"24763_CR32","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1016\/S2213-2600(16)30279-X","volume":"4","author":"M Castro","year":"2016","unstructured":"Castro, M., Zangrilli, J. & Wechsler, M. E. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials (vol 3, pg 355, 2015). Lancet Respir. Med. 4, E50 (2016).","journal-title":"Lancet Respir. Med."},{"key":"24763_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.anai.2018.08.005","volume":"122","author":"J Corren","year":"2019","unstructured":"Corren, J. et al. Dupilumab improves symptoms, quality of life and productivity in uncontrolled persistent asthma. Ann. Allergy Asthma Immunol. 122, 41\u201349 (2019).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"24763_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1183\/09031936.00223411","volume":"41","author":"E Piper","year":"2013","unstructured":"Piper, E. et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 41, 330\u2013338 (2013).","journal-title":"Eur. Respir. J."},{"key":"24763_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","volume":"181","author":"M Castro","year":"2010","unstructured":"Castro, M. et al. Asthma intervention research 2 (AIR2) trial. Am. J. Respir. Crit. Care Med. 181, 116\u2013124 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"24763_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1103319","volume":"365","author":"ME Wechsler","year":"2011","unstructured":"Wechsler, M. E. et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N. Engl. J. Med. 365, 119\u2013126 (2011).","journal-title":"N. Engl. J. Med."},{"key":"24763_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","volume":"9","author":"S Diver","year":"2021","unstructured":"Diver, S. et al. Effect of tezepelumab on airway inflammatory cells, remodelling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 1299\u20131312 (2021).","journal-title":"Lancet Respir. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24763-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24763-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24763-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:01:56Z","timestamp":1670360516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24763-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24763"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24763-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20905"}}